In addition to breast cancer, the synergistic anti-tumor effect of dual inhibition of the PI3K/AKT/mTOR pathway and CDK4/6 has also been demonstrated in malignant pleural mesothelioma, T-cell acute lymphoblastic leukemia, and mantle cell lymphomas49–51. This evidence concerns the gene CDK4 and neoplasm.